≡

Multiplex Assay Kit for Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay)

Monocyte differentiation antigen CD14; Myeloid cell-specific leucine-rich glycoprotein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 88-95 92
EDTA plasma(n=5) 78-101 82
heparin plasma(n=5) 80-101 87
sodium citrate plasma(n=5) 85-101 89

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 98-105% 87-98% 87-99% 79-94%
EDTA plasma(n=5) 78-104% 80-103% 79-89% 88-102%
heparin plasma(n=5) 85-105% 79-102% 85-99% 86-96%
sodium citrate plasma(n=5) 93-101% 94-102% 82-91% 80-98%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:CD14) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of Pharmacology and Experimental Therapeutics Successful Treatment of Acute Lung Injury with Pitavastatin in Septic Mice: Potential Role of Glucocorticoid Receptor Expression in Alveolar Macrophages Aspet: 171462
Tumour Biol Elevated serum soluble CD15 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma PubMed: 26643894
Free Patents online RHEUMATOID ARTHRITIS RELATED BIOMARKER 20170350884
Intensive Care Research Evaluating the Roles of sCD14 and sCD14-ST in Diagnosing COPD and Predicting an Acute Exacerbation of COPD
Catalog No. Related products for research use of Sus scrofa; Porcine (Pig) Organism species Applications (RESEARCH USE ONLY!)
RPA685Po01 Recombinant Cluster Of Differentiation 14 (CD14) Positive Control; Immunogen; SDS-PAGE; WB.
PAA685Po01 Polyclonal Antibody to Cluster Of Differentiation 14 (CD14) WB; IHC; ICC; IP.
MAA685Po21 Monoclonal Antibody to Cluster Of Differentiation 14 (CD14) WB; IHC; ICC; IP.
SEA685Po ELISA Kit for Cluster Of Differentiation 14 (CD14) Enzyme-linked immunosorbent assay for Antigen Detection.
LMA685Po Multiplex Assay Kit for Cluster Of Differentiation 14 (CD14) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.